Kyle W Eudailey, MD (@KyleEudaileyMD) header
Kyle W Eudailey, MD (@KyleEudaileyMD) profile picture

Kyle W Eudailey, MD

@KyleEudaileyMD

Assistant Prof of Cardiothoracic Surgery @UABmedicine. Specializing in Structural Heart/TAVR, Aortic Surgery, Aortic Valve Repair, & Hybrid/Endo Aortic Repair

 Birmingham, AL
uab.edu/medicine/surgery/cardiothoracic/faculty/eudailey
Joined October 2017
  • Tweets995
  • Following513
  • Followers1.8K
24Media
Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)Photo by Kyle W Eudailey, MD (@KyleEudaileyMD)
Remember the power of an Omental Flap for lnfected Aortas! Infected Aortic grafts are an unfortunate complication in our business. Complete resection usually the only cure. Here is redo zone 2 total arch. Rifampin soaked graft and omental flap. #AortaED @UABSurgery
14
61
6
375
This is spectacular!
Daniel Gallardo-Gómez (@DanielG12754470) profile pictureDaniel Gallardo-Gómez@DanielG12754470Oct 29
Built an aortic root viewer with @claudeai Opus 5.5 🫀 Enter body size + measured diameters → a beating 3D heart compares your aorta with a standard one, with echo-style scans, ACC/AHA & ESC 2024 thresholds and a PDF report (EN/ES). Based on @AnnasRahmanMD cardio tool.
3
15
1,550
Kyle W Eudailey, MD retweeted
Daniel Gallardo-Gómez (@DanielG12754470) profile picture
Daniel Gallardo-Gómez@DanielG12754470Oct 29
Built an aortic root viewer with @claudeai Opus 5.5 🫀 Enter body size + measured diameters → a beating 3D heart compares your aorta with a standard one, with echo-style scans, ACC/AHA & ESC 2024 thresholds and a PDF report (EN/ES). Based on @AnnasRahmanMD cardio tool.
8
21
1
136
8,298
Kyle W Eudailey, MD retweeted
JACC Journals (@JACCJournals) profile picture
JACC Journals@JACCJournalsOct 29
In an international cohort of 230 pts undergoing DCB-PCI for de novo #CAD, baseline physiological pattern influenced procedural results. ➡️ Diffuse vs focal disease showed smaller acute μFR gain & more suboptimal post-PCI physiology. #JACCAsia #PCI bit.ly/4eAarq4
Image from JACC Journals (@JACCJournals)
2
15
3
52
6,909
Kyle W Eudailey, MD retweeted
EJPC Editor-in-Chief (@EJPCEiC) profile picture
EJPC Editor-in-Chief@EJPCEiCOct 27
Is apoB alone enough to capture lipoprotein-related coronary risk? In>40,000 participants across ethnic groups, risk-weighted apoB(incorporating triglycerides and Lp(a)) captured additional coronary risk, with modest improvements in risk discrimination. 🔗doi.org/10.1093/eurjpc/zwag5…
Image from EJPC Editor-in-Chief (@EJPCEiC)
9
40
3,432
Kyle W Eudailey, MD retweeted
JACC Journals (@JACCJournals) profile picture
JACC Journals@JACCJournalsOct 25
#JACCINT: In 466 propensity-matched pairs requiring pacemaker after #TAVR, conduction system pacing was tied to lower CV death or HFH compared to RV pacing (9.7% vs 17.6%; p=0.003). Pacing strategy may be a modifiable determinant of long-term outcomes. bit.ly/4BoueCK
Image from JACC Journals (@JACCJournals)
2
20
3
49
6,454
Kyle W Eudailey, MD retweeted
The Kobeissi Letter (@KobeissiLetter) profile picture
The Kobeissi Letter
@KobeissiLetterOct 27
Hospitals using AI are seeing better healthcare outcomes. In 2023, health systems with high and low AI use had the same death rate: ~1,600 per 100,000 patients. By 2026, the systems using AI the most dropped to ~1,000 deaths per 100,000. That's a decline of nearly 40% in just 3 years. Meanwhile, hospitals with lower AI adoption have seen significantly smaller improvements. The gap in patient outcomes is widening as AI adoption accelerates. AI is rapidly transforming healthcare.
🤝 Paid partnership
Image from The Kobeissi Letter (@KobeissiLetter)
Ali Khokhar (@khookhar) profile pictureAli Khokhar
@khookharOct 27
Today, we’re introducing the next chapter of Concurrence and the world’s greatest leap toward Superintelligent Care. When I was 13 I lost my mom to cancer that should’ve been caught earlier. We’re building a system that sees every patient’s future in time to change the outcome
105
228
51
2,033
245,796
The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia names South Asian ancestry and elevated Lp(a) levels as risk-enhancing considerations that should prompt closer scrutiny rather than reflexive statin initiation. Read more: bit.ly/4dWzaEU #ACCPrev
Image from American College of Cardiology (@ACCinTouch)
1
18
3
64
14,530
Kyle W Eudailey, MD retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMOct 24
POET II: For patients with infective endocarditis on the left side of the heart, the recommendation of up to 6 weeks of antibiotics is largely based on expert consensus opinion. Research findings on a response-tailored antibiotic strategy are summarized in a new Quick Take video. nej.md/4gxdLCy #ESCCongress
A detailed illustration of infective endocarditis on the left side of the heart. Accompanying the heart image are pills, medication bottles, a box, and a monthly calendar.

ALT A detailed illustration of infective endocarditis on the left side of the heart. Accompanying the heart image are pills, medication bottles, a box, and a monthly calendar.

3
30
1
134
21,868
Kyle W Eudailey, MD retweeted
Eric Topol (@EricTopol) profile picture
Eric Topol
@EricTopolOct 22
Just published @ScienceMagazine Higher medical accuracy at lower cost A 3-agent AI for sequential diagnosis nearly doubled accuracy compared with physicians for >300 @NEJM CPC cases and >300 ER cases AND substantially lowered cost, also exceeded performance of many AI models, physicians plus AI @HarshaNori @erichorvitz @Dominic1King @mustafasuleyman
Image from Eric Topol (@EricTopol)
40
129
19
497
61,744
Kyle W Eudailey, MD retweeted
Adaptyv Bio (@adaptyvbio) profile picture
Adaptyv Bio
@adaptyvbioOct 20
We're excited to share results from our latest wet lab campaign with @AnthropicAI and @citrini. Claude designed novel proteins to neutralize scorpion toxins and we tested 211 of these protein designs in our automated wet lab. 17 of them showed binding to the toxins in our experiments, with all data now available on @proteinbase. This is a great example of what we're building towards: A world where anyone can run drug discovery campaigns on our automated wet lab.
21
81
18
510
35,672
Kyle W Eudailey, MD retweeted
Mohammed Kamareddine, MD (@m__kamareddine) profile picture
Mohammed Kamareddine, MD
@m__kamareddineOct 19
Apple is taking its sweet time reviewing EchoSuite, so rather than keep waiting, I’ve decided to launch it on the web! The upside is that It is available to everyone. 🌐 echosuite.app EchoSuite brings together a real-time, anatomically labeled TTE simulator with interactive coaching and a fully adjustable 3D scene to make things more intuitive. It also includes echo calculators, and illustrations to guide you through image acquisition and measurements.
Echo Simulator Online | 3D Echocardiography | EchoSuite

Echo Simulator Online | 3D Echocardiography | EchoSuite

Practice 15 TTE views in a 3D echo simulator online. Move the probe, explore simulated ultrasound and clinical reference cines. No sign-in or installation.

echosuite.app
12
74
2
373
28,925
Kyle W Eudailey, MD retweeted
Anthropic (@AnthropicAI) profile picture
Anthropic
@AnthropicAIOct 20
New on our Science Blog: designing protein binders against scorpion neurotoxins. Scorpions sting about 1.2m people every year, and antivenoms are often costly or in short supply. Claude has made an early step toward finding new treatments. anthropic.com/research/claud…
How Claude designed protein binders against scorpion neurotoxins

How Claude designed protein binders against scorpion neurotoxins

We asked an internal research Claude model to design minibinders (small proteins that attach tightly to a target) against scorpion neurotoxins.

anthropic.com
505
613
377
7,347
1,823,999
Kyle W Eudailey, MD retweeted
JACC Journals (@JACCJournals) profile picture
JACC Journals@JACCJournalsOct 19
In this #JACCINT meta-analysis of 4 RCTs (n=2,651 #STEMI + multivessel disease), immediate complete revascularization was associated w/ ⬆️ 1-year all-cause mortality vs staged (HR 1.50)—but reduced MI (HR 0.58). bit.ly/4B9eKm9
Image from JACC Journals (@JACCJournals)
2
21
59
6,252
New in #EJPC: Beyond one-size-fits-all cardiovascular prevention. A new review explores pathway-guided, patient-centered strategies targeting lipids, inflammation, thrombosis, and endothelial dysfunction to address residual risk and personalize treatment. 🔗 ow.ly/G7OB50ZYKf6
Image from European Society of Cardiology Journals (@ESC_Journals)
5
34
4
112
8,004
Kyle W Eudailey, MD retweeted
JACC Journals (@JACCJournals) profile picture
JACC Journals@JACCJournalsOct 15
🆕 ACC Scientific Statement: Exercise is a foundational component of #CVD prevention & treatment. The biggest drop in CV risk happens when sedentary people become more active. Exercise prescriptions should be safe, personalized, achievable, & sustainable. bit.ly/4hxfedX
Image from JACC Journals (@JACCJournals)
2
71
5
167
7,326
Kyle W Eudailey, MD retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMOct 14
Presented at #LIVES2026: An open-label, randomized, noninferiority trial showed that intermittent hemodialysis was not noninferior to continuous renal-replacement therapy in critically ill adults with acute kidney injury. Full ICRAKI trial results: nej.md/472QMel Editorial: Continuous or Intermittent Renal-Replacement Therapy — What is the Question? nej.md/4egLaB1
A graph from the Original Article "Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury." The trial name, ICRAKI, is in parentheses after the title. The graph shows the cumulative probability of death from randomization through day 90, as estimated with the Kaplan–Meier method. The trial results are being presented at the European Society of Intensive Care Medicine. The logo of the New England Journal of Medicine is at the bottom.

ALT A graph from the Original Article "Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury." The trial name, ICRAKI, is in parentheses after the title. The graph shows the cumulative probability of death from randomization through day 90, as estimated with the Kaplan–Meier method. The trial results are being presented at the European Society of Intensive Care Medicine. The logo of the New England Journal of Medicine is at the bottom.

13
134
15
432
91,928
Kyle W Eudailey, MD retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMOct 9
Original Article: Tricuspid-Valve Intervention in Heart Failure (TRIC-I-HF trial) nej.md/4ilZJGr Editorial: Transcatheter Tricuspid-Valve Intervention for Severe Tricuspid Regurgitation nej.md/4hGHKZf #Cardiology #ESCCongress
Three graphs showing Kaplan–Meier estimates for prespecified events as adjudicated by the clinical-events committee at 3 years. Panel A shows freedom from death from any cause or hospitalization for heart failure (second coprimary end point), Panel B survival, and Panel C freedom from hospitalization for heart failure.

ALT Three graphs showing Kaplan–Meier estimates for prespecified events as adjudicated by the clinical-events committee at 3 years. Panel A shows freedom from death from any cause or hospitalization for heart failure (second coprimary end point), Panel B survival, and Panel C freedom from hospitalization for heart failure.

2
38
1
89
18,447
Kyle W Eudailey, MD retweeted
JACC Journals (@JACCJournals) profile picture
JACC Journals@JACCJournalsOct 5
What happens to #MitralRegurgitation after #TAVR—and who is most likely to have persistent MR? Over half of patients w/ moderate-severe MR improved after TAVR. Women & pts w/ severe baseline MR less likely to improve. jacc.org/doi/10.1016/j.jacad… #JACCAdvances #StructuralHeart
Image from JACC Journals (@JACCJournals)
1
32
2
107
5,016
Kyle W Eudailey, MD retweeted
JACC Journals (@JACCJournals) profile picture
JACC Journals@JACCJournalsOct 1
Beta-blockers on autopilot? In this #JACC State-of-the-Art review, revisit where evidence supports treatment and where habit keeps the refills coming. jacc.org/doi/10.1016/j.jacc.… @rcstarling @AndreaRussoEP @DLBHATTMD @MidAmericaHeart
Image from JACC Journals (@JACCJournals)
3
73
1
224
15,875
Kyle W Eudailey, MD retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMSep 30
Original Article: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (phase 3 TRIUMPH-1 trial) nej.md/4ycgSHz #Endocrinology
Two figures showing the effect of retatrutide on body weight. Panel A shows the percent change in body weight from baseline to week 80 (controlled for type I error). Panel B shows the percentage of patients with reductions in body weight of 15% or more and 30% or more (controlled for type I error), along with the percentage of patients who reached the body-mass index targets of less than 30 or less than 25 and the waist-to-height ratio target of less than 0.5 (not controlled for type I error) at week 80 for the treatment-regimen estimand.

ALT Two figures showing the effect of retatrutide on body weight. Panel A shows the percent change in body weight from baseline to week 80 (controlled for type I error). Panel B shows the percentage of patients with reductions in body weight of 15% or more and 30% or more (controlled for type I error), along with the percentage of patients who reached the body-mass index targets of less than 30 or less than 25 and the waist-to-height ratio target of less than 0.5 (not controlled for type I error) at week 80 for the treatment-regimen estimand.

Two figures showing the effect of retatrutide on health outcomes. Panel A shows the percent change in lipid measures, the percent change in the high-sensitivity C-reactive protein (hsCRP), and the change in systolic blood pressure (SBP) in the overall trial population (controlled for type I error except for low-density lipoprotein [LDL] and high-density lipoprotein [HDL]). Panel B shows the percentage of patients with normoglycemia, prediabetes, and type 2 diabetes at week 80 among the patients who had prediabetes at baseline for the treatment-regimen data-points set.

ALT Two figures showing the effect of retatrutide on health outcomes. Panel A shows the percent change in lipid measures, the percent change in the high-sensitivity C-reactive protein (hsCRP), and the change in systolic blood pressure (SBP) in the overall trial population (controlled for type I error except for low-density lipoprotein [LDL] and high-density lipoprotein [HDL]). Panel B shows the percentage of patients with normoglycemia, prediabetes, and type 2 diabetes at week 80 among the patients who had prediabetes at baseline for the treatment-regimen data-points set.

4
54
7
220
105,342
Load more